NCT03502850 - Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer | Biotech Hunter

Enrollment

507

Participants

Timeline

Start Date

November 30, 2017

Primary Completion Date

January 31, 2021

Study Completion Date

August 31, 2021

Conditions

Locally Advanced or Metastatic NSCLC

Interventions

DRUG

ASK120067

patients take ASK120067 orally once per day at 40,80,160,240,320,480mg

Trial Locations (3)

NOT_YET_RECRUITING

Chinese Academy of Medical Sciences, Beijing

RECRUITING

Beijing Chest Hospital,Capital Medical University, Beijing

NOT_YET_RECRUITING

Tianjin Medical University Cancer Insititute & Hospital, Tianjin